Stock comparison
BioAge Labs
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIOA
BioAge Labs
Market cap
$625.36M
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIOA | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 42D | 65C | GMAB |
| Benjamin Graham | 42D | 64C | GMAB |
| Philip Fisher | 65C | 48D | BIOA |
| Peter Lynch | 4F | 25F | GMAB |
| Joel Greenblatt | 4F | 76B | GMAB |
| Charlie Munger | 61D | 68C | GMAB |
| Terry Smith | 64D | 71C | GMAB |
Side-by-side metrics
| Metric | BIOA | GMAB |
|---|---|---|
| Market cap | $625.36M | $16.5B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | - | 12.0x |
| ROIC (TTM) | -26.51% | 43.78% |
| Gross margin | 99.39% | 93.88% |
| Net margin | -8.72% | 18.23% |
| Revenue CAGR 5y | - | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIOA leads on
- P/E (TTM)-vs 6.2x+180%
- EV/EBIT-vs 12.0x+134%
- Debt / Equity0.0xvs 0.1x+86%
- Gross margin99.39%vs 93.88%+6%
GMAB leads on
- ROIC (TTM)43.78%vs -26.51%+161%
- Net margin18.23%vs -8.72%+102%
- Market cap$16.5Bvs $625.36M+96%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.